🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Repatha 140 mg solution for injection in pre-filled pen

    Pari Pharma GmbH

    acute myocardial infarction

    approved small molecule active

    1 trial

  2. Rescue Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Neovascular Polypoidal Choroidal Vasculopathy

    approved small molecule active

    1 trial

  3. Reslizumab

    Teva Pharma GmbH

    Asthma

    approved small molecule active

    5 trials

  4. Reslizumab

    Teva Pharma GmbH

    Asthma; Eosinophilic

    approved mab completed

    1 trial

  5. Reveal® XT Insertable Cardiac Monitor

    Rhythm Pharmaceuticals Netherlands B.V.

    Cryptogenic Symptomatic Transient Ischemic Attack

    approved other completed

    1 trial

  6. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  7. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial

  8. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial

  9. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  10. Rifaximin Oral Tablet

    Hospital Authority, Hong Kong

    Irritable Bowel Syndrome With Diarrhea

    approved small molecule completed

    1 trial

  11. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

  12. Rivaroxaban 2.5 MG Oral Tablet [Xarelto]

    The University of Hong Kong

    Atherosclerosis, Coronary

    approved small molecule completed

    1 trial

  13. Rivaroxaban 2.5 mg

    Second Xiangya Hospital of Central South University

    Acute Coronary Syndrome

    approved small molecule completed

    1 trial

  14. Rocuronium Bromide

    ELITE PHARMACEUTICALS INC /NV/

    Muscle Relaxation

    approved small molecule completed

    1 trial

  15. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    ITCH

    approved small molecule active

    1 trial

  16. Roflumilast alternated days

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule completed

    1 trial

  17. Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning

    The George Institute

    lumbar arthrodesis

    approved small molecule active

    1 trial

  18. Rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infarction, Anterior Cerebral Artery

    approved small molecule active

    1 trial

  19. Rosuvastatin and Ezetimibe morning or evening administration

    COLLEGIUM PHARMACEUTICAL, INC

    Hypercholesterolemia

    approved small molecule completed

    1 trial

  20. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  21. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

  22. SALBUTAMOL

    United Therapeutics Europe Ltd

    CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    approved small molecule completed

    1 trial

  23. SCE-B

    Teva Pharma GmbH

    Nocturnal Vasomotor Symptoms

    approved small molecule completed

    1 trial

  24. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources